BioSpace News Archive

The American Society of Plastic Surgeons – the world’s largest plastic surgery organization – leads the specialty’s medical professionals in navigating their practices’ recovery plans.

Study to evaluate simultaneous blockade of PVRIG, TIGIT and PD-1 immune checkpoints Study to accelerate clinical evaluation of Compugen’s DNAM axis hypothesis and biomarker-driven approach in advanced solid tumors to broaden patient population responsive to cancer immunotherapy On-track to begin triple combination study during second half of 2020

Regeneron and Intellia to co-develop potential hemophilia A and B treatments using their jointly-owned targeted transgene insertion capabilities

CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind, placebo-controlled mu

Vivet Therapeutics announced that both the Food and Drug Administration and the European Commission have granted Orphan Drug Designation for Vivet’s second gene therapy product, VTX-803, for the treatment of Progressive Familial Intrahepatic Cholestasis type 3.

New BRILINTA indication expands treatment to high-risk coronary patients without a history of stroke or heart attack

LabCorp, a leading global life sciences company that is deeply integrated in guiding patient care, announced that Covance, its drug development business, has created COVID-19 Clinical Trial Connect in the U.S., a site designed to help people access information about how to participate in COVID-19 research.

As part of its broad-ranging response to help protect frontline healthcare professionals during the COVID-19 pandemic, Honda engineers have developed new methods to use manufacturing equipment to produce critically needed face shields and have donated 70,000 face shields to healthcare workers at 305 medical facilities in 45 states to date with plans to donate another 60,000 in the coming days.

Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, announced the initiation of a clinical study to explore the use of an extracorporeal medical device to remove excess Beta-2 microglobulin from circulation for the treatment of cognitive impairment in patients undergoing hemodialysis for end stage renal disease.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, announced its participation in two upcoming investor conferences.